Document Detail


Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.
MedLine Citation:
PMID:  20824397     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
BACKGROUND: The maximum standardized uptake value (SUV(max)) on (18)F-fluorodeoxyglucose-positron emission tomography ((18)F-FDG PET) within the primary tumor may predict outcome in patients with surgically resected non-small cell lung cancer (NSCLC). However, it remains uncertain whether the SUV(max) of the primary tumor predicts outcome after chemotherapy in advanced NSCLC. Thus, we evaluated the ratio of SUV(max) of the metastatic tumor to the primary tumor (M/P ratio) to determine whether it could be a useful marker in predicting response and outcome after chemotherapy in advanced NSCLC.
METHODS: Chemo-naïve patients with advanced NSCLC who had locoregional lymph nodes and/or distant metastases other than brain, were eligible for inclusion in this study. Response and survival were analyzed according to the SUV(max) of primary tumor, the ratio of the SUV(max) of the tumor to the mean SUV of the mediastinum (T/M ratio) and M/P ratio.
RESULTS: One hundred and four consecutive patients were included in the retrospective study. Patients with high M/P ratio exhibited significantly lower response rates. The value of SUV(max) and T/M ratio were not associated with the response to initial chemotherapy. In the univariate analysis, T/M ratio and SUV(max) were significantly associated with poor outcome. However, the outcome of non-adenocarcinoma was unaffected by T/M ratio and SUV(max). Multivariate analysis confirmed that high M/P ratio was a significant independent factor predicting a poor outcome.
CONCLUSION: High M/P ratio was associated with a poor response to initial chemotherapy and was a significant independent factor in predicting poor outcome in advanced NSCLC patients with metastatic tumors other than in brain.
Authors:
Kyoichi Kaira; Masahiro Endo; Koiku Asakura; Asuka Tsuya; Yukiko Nakamura; Tateaki Naito; Haruyasu Murakami; Toshiaki Takahashi; Nobuyuki Yamamoto
Related Documents :
18671847 - Neoadjuvant therapy monitoring with pet and ct in esophageal cancer (neopec-trial).
23912397 - Tracheal stenting has minimal impact on survival in anaplastic thyroid carcinoma.
9704967 - Positron emission tomography plus serum ta90 immune complex assay for detection of occu...
18051657 - Variation in responses of late-seral herbs to disturbance and environmental stress.
19204207 - Randomized phase ii trial of erlotinib versus temozolomide or carmustine in recurrent g...
3565317 - Combined therapy as an alternative to exenteration for locally advanced vulvovaginal ca...
Publication Detail:
Type:  Journal Article     Date:  2010-09-08
Journal Detail:
Title:  Annals of nuclear medicine     Volume:  24     ISSN:  1864-6433     ISO Abbreviation:  Ann Nucl Med     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-12-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8913398     Medline TA:  Ann Nucl Med     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  697-705     Citation Subset:  IM    
Affiliation:
Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. kkaira1970@yahoo.co.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A simple test to determine the quality of your clinical PET images.
Next Document:  Iodine-123-metaiodobenzylguanidine imaging can predict future cardiac events in heart failure patien...